<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410499</url>
  </required_header>
  <id_info>
    <org_study_id>MLN1202-2005</org_study_id>
    <secondary_id>2014-005142-21</secondary_id>
    <secondary_id>U1111-1168-1426</secondary_id>
    <nct_id>NCT02410499</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy in Subjects With Macroalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the effects of 85 days treatment with MLN1202 on&#xD;
      urinary albumin-to-creatinine ratio (UACR) in participants with type 2 diabetes, advanced&#xD;
      kidney disease/diabetic nephropathy (DN) and macro-albuminuria (UACR&gt;300 mg/g) based on&#xD;
      average of 3 consecutive first morning voids sample collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called MLN1202. MLN1202 is being tested to treat&#xD;
      people who have diabetes with macroalbuminuria. This study will look at the urinary&#xD;
      albumin-to-creatinine ratio in people who take MLN1202.&#xD;
&#xD;
      The study will enroll approximately 156 patients. Participants will be randomly assigned (by&#xD;
      chance, like flipping a coin) to one of the four treatment groups-which will remain&#xD;
      undisclosed to the patient and study doctor during the study (unless there is an urgent&#xD;
      medical need):&#xD;
&#xD;
        -  MLN1202 75 mg subcutaneous (SC) injection&#xD;
&#xD;
        -  MLN1202 105 mg SC injection&#xD;
&#xD;
        -  MLN1202 150 mg SC injection&#xD;
&#xD;
        -  Placebo matching MLN1202 SC injection (dummy inactive solution) - this is a solution&#xD;
           that looks like the study drug but has no active ingredient&#xD;
&#xD;
      All participants will receive a loading dose of placebo or MLN1202 on Day 1 followed by&#xD;
      once-weekly injections of the study medication they were randomized to receive.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The overall time to participate in this&#xD;
      study is 5 months. Participants will make multiple visits to the clinic, plus a final visit 5&#xD;
      weeks after the last dose of study drug for a follow-up assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Actual">November 17, 2015</completion_date>
  <primary_completion_date type="Actual">November 17, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Day 85</measure>
    <time_frame>Baseline and Day 85</time_frame>
    <description>UACR will be calculated using the geometric mean of 3 consecutive days first in the morning urine voids. First morning void is defined as a void upon awakening and before beginning daily activities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Over Time</measure>
    <time_frame>Baseline and Days 29, 57, 85, and 113</time_frame>
    <description>For Days 29 and 57 UACR will be evaluated from a single first morning void. For Days 85 and 113 UACR will be calculated using the geometric mean of 3 consecutive days first in the morning urine voids. First morning void is defined as a void upon awakening and before beginning daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Urinary Protein:Creatinine Ratio (UPCR) Over Time</measure>
    <time_frame>Baseline and Days 29, 57, 85, and 113</time_frame>
    <description>For Days 29 and 57 UPAR will be evaluated from a single first morning void. For Days 85 and 113 UPCR will be calculated using the geometric mean of 3 consecutive days first in the morning urine voids. First morning void is defined as a void upon awakening and before beginning daily activities.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MLN1202 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MLN1202 105 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MLN1202 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN1202 Placebo</intervention_name>
    <description>MLN1202 placebo-matching solution for SC injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN1202</intervention_name>
    <description>MLN1202 solution for SC injection</description>
    <arm_group_label>MLN1202 105 mg</arm_group_label>
    <arm_group_label>MLN1202 150 mg</arm_group_label>
    <arm_group_label>MLN1202 75 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, the participant is capable of giving informed&#xD;
             consent to enter the trial, including understanding and complying with protocol&#xD;
             requirements.&#xD;
&#xD;
          2. The participant or, when applicable, (eg, where the subject is capable of giving&#xD;
             verbal informed consent to enter the trial but cannot physically sign a written,&#xD;
             informed consent form), the participant's legally acceptable representative signs and&#xD;
             dates a written, informed consent form and any required privacy authorization prior to&#xD;
             the initiation of any study procedures.&#xD;
&#xD;
          3. At the time of Screening the participant is male or female and aged 18-90 years&#xD;
             inclusive at first dose of study medication.&#xD;
&#xD;
          4. Was previously diagnosed with type 2 diabetes mellitus per American Diabetes&#xD;
             Association criteria.&#xD;
&#xD;
          5. Has an estimated glomerular filtration rate (eGFR) based on serum creatinine (eGFR,&#xD;
             determined by Modification of Diet in Renal Disease [MDRD] equation) of 25-59&#xD;
             mL/min/1.73 m(2) at Screening.&#xD;
&#xD;
          6. Has been on a stable dose of angiotensin-converting enzyme (ACE) inhibitor or&#xD;
             angiotensin II receptor blocker (ARB) for 8 weeks prior to Screening.&#xD;
&#xD;
          7. Has residual albuminuria despite stable treatment with an ACE inhibitor or an ARB for&#xD;
             at least 8 weeks prior to Screening (albumin:creatinine ratio [ACR] of &gt; 300 mg/g&#xD;
             creatinine, inclusive at Screening).&#xD;
&#xD;
          8. Has glycosylated hemoglobin (HbA1c) less than or equal to 10.5% at screening.&#xD;
&#xD;
          9. If a subject is regularly using dipeptidyl peptidase-4 inhibitor (DPP-4i) or&#xD;
             sodium-glucose cotransporter 2 inhibitor (SGLT2i) to treat diabetes, he/she has been&#xD;
             on a stable dose and regimen within 2 months prior to Screening.&#xD;
&#xD;
         10. All participants who are not surgically sterile or post-menopausal, or whose partners&#xD;
             are not surgically-sterile or postmenopausal, must use two effective birth control&#xD;
             methods or abstain from intercourse during this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has received any investigational compound within 90 days prior to Screening.&#xD;
&#xD;
          2. Is an immediate family member, study site employee, or is in a dependant relationship&#xD;
             with a study site employee who is involved in the conduct of this study (eg, spouse,&#xD;
             parent, child, sibling) or may consent under duress.&#xD;
&#xD;
          3. Is taking any combination of dual renin-angiotensin system (RAS) inhibition (such as&#xD;
             an ACE inhibitor and an ARB or an ACE inhibitor and a mineralocorticoid receptor&#xD;
             antagonist).&#xD;
&#xD;
          4. Has type 1 diabetes mellitus or a history of ketoacidosis.&#xD;
&#xD;
          5. Has poorly-controlled blood pressure (systolic blood pressure &gt;160 or diastolic blood&#xD;
             pressure &gt;110, with blood pressure measured in the seated position after at least 5&#xD;
             minutes of rest) at Screening and Day 1.&#xD;
&#xD;
          6. Has received dialysis within 3 months of Screening.&#xD;
&#xD;
          7. Has infectious diseases or leg ulcers at Screening (all per discretion of Principal&#xD;
             Investigator [PI]).&#xD;
&#xD;
          8. Has severe concurrent disease which, in the judgment of the investigator, would&#xD;
             interfere significantly with the assessments of safety and efficacy during this study.&#xD;
&#xD;
          9. Has known infection with human immunodeficiency virus (HIV), or a positive test for&#xD;
             Hepatitis B, Hepatitis C, or tuberculosis (TB) at Screening. Subjects who have a&#xD;
             positive TB skin test at Screening must rule out active or latent tuberculosis&#xD;
             documented by chest x-ray in order to be considered eligible for study participation.&#xD;
&#xD;
         10. Has used long-term immune suppressants, steroid therapy (except for topical use or&#xD;
             inhalation), chronic use of non-steroidal anti-inflammatory drug (NSAIDs),&#xD;
             cyclooxygenase type 2 (COX-2) inhibitors within 2 weeks prior to Screening. Short-term&#xD;
             use is defined as a duration of â‰¤4 weeks of continuous use.&#xD;
&#xD;
         11. In the judgment of the principal investigator, participants who are likely to be&#xD;
             non-compliant or uncooperative during the study.&#xD;
&#xD;
         12. Has known non-diabetic kidney disease (such as autosomal dominant polycystic kidney&#xD;
             disease (ADPCKD), Immunoglobulin A (IgA) nephropathy, focal segmental&#xD;
             glomerulosclerosis, or obstructive uropathy). Hypertensive nephrosclerosis&#xD;
             superimposed on diabetic kidney disease is acceptable.&#xD;
&#xD;
         13. Had a previous renal transplant.&#xD;
&#xD;
         14. Has hypersensitivity to other monoclonal antibodies (mAb) or to any component of the&#xD;
             formulation of MLN1202.&#xD;
&#xD;
         15. Has history of malignancy within the previous 5 years (with the exception of&#xD;
             adequately treated basal cell or squamous cell carcinoma of the skin).&#xD;
&#xD;
         16. Is symptomatic with dysuria, and has a positive urine culture at screening.&#xD;
&#xD;
         17. If female, the subject is pregnant or lactating or intending to become pregnant&#xD;
             before, during, or within 1 month after participating in this study; or intending to&#xD;
             donate ova during such time period and for 56 days (8weeks) afterwards.&#xD;
&#xD;
         18. If male, the subject intends to donate sperm during the course of this study or for 12&#xD;
             weeks thereafter.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

